Assembly Biosciences Inc. (ASMB)
Assembly Biosciences Statistics
Share Statistics
Assembly Biosciences has 7.5M shares outstanding. The number of shares has increased by 21.69% in one year.
Shares Outstanding | 7.5M |
Shares Change (YoY) | 21.69% |
Shares Change (QoQ) | 18.05% |
Owned by Institutions (%) | 0.01% |
Shares Floating | 3.95M |
Failed to Deliver (FTD) Shares | 200 |
FTD / Avg. Volume | 0.73% |
Short Selling Information
The latest short interest is 16.42K, so 0.26% of the outstanding shares have been sold short.
Short Interest | 16.42K |
Short % of Shares Out | 0.26% |
Short % of Float | 0.47% |
Short Ratio (days to cover) | 0.41 |
Valuation Ratios
The PE ratio is -2.36 and the forward PE ratio is -1.8. Assembly Biosciences's PEG ratio is 0.05.
PE Ratio | -2.36 |
Forward PE | -1.8 |
PS Ratio | 3.32 |
Forward PS | 1.9 |
PB Ratio | 2.84 |
P/FCF Ratio | -1.85 |
PEG Ratio | 0.05 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Assembly Biosciences.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.42, with a Debt / Equity ratio of 0.09.
Current Ratio | 2.42 |
Quick Ratio | 2.42 |
Debt / Equity | 0.09 |
Debt / EBITDA | -0.07 |
Debt / FCF | -0.06 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $390.68K |
Profits Per Employee | $-550.37K |
Employee Count | 73 |
Asset Turnover | 0.24 |
Inventory Turnover | n/a |
Taxes
Income Tax | 330K |
Effective Tax Rate | -0.83% |
Stock Price Statistics
The stock price has increased by -32.34% in the last 52 weeks. The beta is 0.63, so Assembly Biosciences's price volatility has been higher than the market average.
Beta | 0.63 |
52-Week Price Change | -32.34% |
50-Day Moving Average | 12.28 |
200-Day Moving Average | 14.79 |
Relative Strength Index (RSI) | 31.3 |
Average Volume (20 Days) | 27.39K |
Income Statement
In the last 12 months, Assembly Biosciences had revenue of 28.52M and earned -40.18M in profits. Earnings per share was -6.69.
Revenue | 28.52M |
Gross Profit | 28.52M |
Operating Income | -45.42M |
Net Income | -40.18M |
EBITDA | -45.42M |
EBIT | -45.42M |
Earnings Per Share (EPS) | -6.69 |
Balance Sheet
The company has 38.34M in cash and 3.09M in debt, giving a net cash position of 35.26M.
Cash & Cash Equivalents | 38.34M |
Total Debt | 3.09M |
Net Cash | 35.26M |
Retained Earnings | -825.92M |
Total Assets | 119.17M |
Working Capital | 67.7M |
Cash Flow
In the last 12 months, operating cash flow was -51.12M and capital expenditures -28K, giving a free cash flow of -51.15M.
Operating Cash Flow | -51.12M |
Capital Expenditures | -28K |
Free Cash Flow | -51.15M |
FCF Per Share | -8.52 |
Margins
Gross margin is 100%, with operating and profit margins of -159.26% and -140.87%.
Gross Margin | 100% |
Operating Margin | -159.26% |
Pretax Margin | -139.72% |
Profit Margin | -140.87% |
EBITDA Margin | -159.26% |
EBIT Margin | -159.26% |
FCF Margin | -179.33% |
Dividends & Yields
ASMB does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for ASMB is $33, which is 253.7% higher than the current price. The consensus rating is "Buy".
Price Target | $33 |
Price Target Difference | 253.7% |
Analyst Consensus | Buy |
Analyst Count | 3 |
Stock Splits
The last stock split was on Feb 12, 2024. It was a backward split with a ratio of 1:12.
Last Split Date | Feb 12, 2024 |
Split Type | backward |
Split Ratio | 1:12 |
Scores
Altman Z-Score | -9.54 |
Piotroski F-Score | 2 |